A detailed history of Northern Trust Corp transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 158,771 shares of CADL stock, worth $1.43 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
158,771
Previous 43,445 265.45%
Holding current value
$1.43 Million
Previous $269,000 308.92%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.02 - $7.76 $578,936 - $894,929
115,326 Added 265.45%
158,771 $1.1 Million
Q2 2024

Aug 14, 2024

BUY
$1.68 - $14.0 $40,215 - $335,132
23,938 Added 122.71%
43,445 $269,000
Q1 2024

May 14, 2024

SELL
$1.21 - $1.86 $133 - $204
-110 Reduced 0.56%
19,507 $30,000
Q1 2023

May 15, 2023

BUY
$1.35 - $2.72 $6,930 - $13,964
5,134 Added 35.45%
19,617 $26,000
Q2 2022

Aug 12, 2022

BUY
$3.13 - $5.56 $3,217 - $5,715
1,028 Added 7.64%
14,483 $47,000
Q4 2021

Feb 08, 2022

BUY
$6.34 - $11.9 $85,304 - $160,114
13,455 New
13,455 $105,000

Others Institutions Holding CADL

About Candel Therapeutics, Inc.


  • Ticker CADL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,891,900
  • Market Cap $260M
  • Description
  • Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...
More about CADL
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.